Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 3,477
Out of 4,412 analysts
11
Total ratings
9.09%
Success rate
-44.36%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Overweight | $8 | $1.89 | +323.28% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $1.64 | +509.76% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $58.46 | +43.69% | 1 | Aug 16, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $8.29 | - | 2 | Apr 4, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $14.92 | +168.10% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $9.21 | +19.44% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $0.90 | +677.86% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $2.59 | +710.81% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | n/a | $0.37 | - | 1 | Oct 14, 2021 |
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $1.89
Upside: +323.28%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $1.64
Upside: +509.76%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $58.46
Upside: +43.69%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Hold
Price Target: n/a
Current: $8.29
Upside: -
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $14.92
Upside: +168.10%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $9.21
Upside: +19.44%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $0.90
Upside: +677.86%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $2.59
Upside: +710.81%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: n/a
Current: $0.37
Upside: -